BLA 761029 · Biogen
Zinbryta
Daclizumab · Injection
NovelLast checked: Nov 20, 2026Latest source record: Nov 1, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
May 27, 2016
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
96
17 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Daclizumab" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple SclerosisPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT01064401 · 1,841 participants · Start May 2010 · Primary completion Mar 2014
Drug: BIIB019 (Daclizumab High Yield Process); Interferon beta-1a Placebo and 2 more · For: Relapsing-Remitting Multiple Sclerosis
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 228 sites in all
- MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant PatientsPivotal-lookingCompleted
Ekberg, Henrik, M.D.Individual
NCT00231764 · 1,760 participants · Start Nov 2002 · Primary completion May 2006
Drug: daclizumab · For: Kidney Transplantation
- Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019Pivotal-lookingTerminated
BiogenBiogen (BIIB)
NCT01797965 · 1,501 participants · Start Feb 15, 2013 · Primary completion Sep 24, 2018
Drug: BIIB019 (Daclizumab) · For: Relapsing-Remitting Multiple Sclerosis; Multiple Sclerosis
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 222 sites in all
- Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.Pivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00295594 · 627 participants · Start Mar 2005 · Primary completion Jun 2007
Drug: tacrolimus · For: Liver Transplantation
Sites: Ghent, Belgium; Leuven, Belgium; Liège, Belgium · 41 sites in all
- Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple SclerosisPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT00390221 · 621 participants · Start Feb 2008 · Primary completion May 2011
Drug: BIIB019 (Daclizumab High Yield Process); Placebo · For: Relapsing-Remitting Multiple Sclerosis
Sites: Brno, Czechia; Olomouc, Czechia; Pilsen, Czechia · 56 sites in all
- A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant PatientsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00048152 · 539 participants · Start Dec 2000 · Primary completion Mar 2006
Drug: Corticosteroids; Neoral and 3 more · For: Kidney Transplantation
Sites: Birmingham, Alabama; San Francisco, California; Gainesville, Florida · 36 sites in all
- Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple SclerosisPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT00870740 · 517 participants · Start Feb 2009 · Primary completion May 2012
Drug: BIIB019 (Daclizumab High Yield Process); Placebo · For: Relapsing-Remitting Multiple Sclerosis
Sites: Brno, Czechia; Hraddec Kralove, Czechia; Olomouc, Czechia · 58 sites in all
- A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac TransplantationPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00048165 · 434 participants · Start Aug 1999 · Primary completion Aug 2002
Drug: Daclizumab; Methylprednisolone and 3 more · For: Heart Transplantation
Sites: Birmingham, Alabama; Los Angeles, California; Tampa, Florida · 30 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Reduced exposure to calcineurin inhibitors in renal transplantation.
Ekberg H, Tedesco-Silva H, Demirbas A, et al. · N Engl J Med 2007 · Comparative Study, Multicenter Study
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Tramacere I, Virgili G, Perduca V, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.
Rindi LV, Zaçe D, Braccialarghe N, et al. · Drug Saf 2024 · Systematic Review, Meta-Analysis
- Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.
Shapiro AM, Lakey JR, Ryan EA, et al. · N Engl J Med 2000 · Clinical Trial, Research Support, Non-U.S. Gov't
- Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis.
Ridley B, Minozzi S, Gonzalez-Lorenzo M, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Biogen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.